3.21
price up icon1.90%   0.06
after-market Handel nachbörslich: 3.21
loading
Schlusskurs vom Vortag:
$3.15
Offen:
$3.1
24-Stunden-Volumen:
1.01M
Relative Volume:
1.06
Marktkapitalisierung:
$622.98M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-7.2955
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
-2.13%
1M Leistung:
-2.13%
6M Leistung:
-21.13%
1J Leistung:
+18.01%
1-Tages-Spanne:
Value
$3.085
$3.32
1-Wochen-Bereich:
Value
$2.995
$3.34
52-Wochen-Spanne:
Value
$2.63
$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name
Firmenname
Arbutus Biopharma Corp
Name
Telefon
604-419-3200
Name
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Name
Mitarbeiter
73
Name
Twitter
@arbutusbio
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
ABUS's Discussions on Twitter

Vergleichen Sie ABUS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ABUS
Arbutus Biopharma Corp
3.21 622.98M 12.99M -74.39M -78.92M -0.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-02-02 Hochstufung Jefferies Hold → Buy
2021-02-25 Eingeleitet Jefferies Hold
2020-12-17 Eingeleitet H.C. Wainwright Buy
2020-07-27 Fortgesetzt JMP Securities Mkt Outperform
2020-07-24 Herabstufung Robert W. Baird Outperform → Neutral
2020-05-19 Hochstufung Wedbush Neutral → Outperform
2020-03-06 Hochstufung Chardan Capital Markets Neutral → Buy
2020-02-20 Eingeleitet Robert W. Baird Outperform
2020-02-05 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2019-10-07 Bestätigt B. Riley FBR Buy
2019-10-04 Herabstufung Chardan Capital Markets Buy → Neutral
2018-10-16 Hochstufung B. Riley FBR Neutral → Buy
2018-10-15 Hochstufung Wedbush Underperform → Neutral
2018-10-12 Bestätigt Chardan Capital Markets Buy
2018-07-06 Herabstufung B. Riley FBR, Inc. Buy → Neutral
2018-03-19 Fortgesetzt Chardan Capital Markets Buy
2018-03-19 Herabstufung Wedbush Outperform → Neutral
2018-01-05 Eingeleitet B. Riley FBR, Inc. Buy
2017-04-04 Hochstufung Chardan Capital Markets Neutral → Buy
2017-02-01 Bestätigt Wedbush Outperform
2016-12-13 Herabstufung Chardan Capital Markets Buy → Neutral
2016-11-30 Hochstufung Chardan Capital Markets Neutral → Buy
Alle ansehen

Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten

pulisher
03:35 AM

Alliancebernstein L.P. Has $393,000 Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

03:35 AM
pulisher
Apr 19, 2025

Franklin Resources Inc. Takes $301,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 19, 2025
pulisher
Apr 15, 2025

Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Vanguard Group Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Raymond James Financial Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Wellington Management Group LLP Buys 16,484 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Corebridge Financial Inc. Has $238,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

KLP Kapitalforvaltning AS Invests $84,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 11, 2025
pulisher
Apr 03, 2025

Teacher Retirement System of Texas Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Warminster-Based Arbutus Biopharma Lays Off Over Half of Workforce, Exits Its Headquarters - BUCKSCO.Today

Apr 02, 2025
pulisher
Apr 01, 2025

Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Arbutus Biopharma Corp (NASDAQ: ABUS) – An Analysis Is What You Need - stocksregister.com

Apr 01, 2025
pulisher
Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025
pulisher
Mar 31, 2025

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Mar 31, 2025
pulisher
Mar 30, 2025

Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MSN

Mar 30, 2025
pulisher
Mar 30, 2025

Xponance Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Chardan Capital Reiterates “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Arbutus Biopharma (NASDAQ:ABUS) Trading 4.1% Higher Following Strong Earnings - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma earnings beat by $0.02, revenue fell short of estimates - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus stock gains after 57% workforce cuts (ABUS:NASDAQ) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Was there any good news for Arbutus Biopharma Corp (ABUS) stock in the last session? - uspostnews.com

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma Announces 2024 Financial Results and Strategic Restructuring - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Charles Schwab Investment Management Inc. Acquires 9,955 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Mar 27, 2025
pulisher
Mar 20, 2025

Arbutus Biopharma Co-Founder Dr. Michael Sofia to Retire After a Storied Career in Antiviral Drug Discovery - MSN

Mar 20, 2025
pulisher
Mar 10, 2025

Reviewing Akari Therapeutics (NASDAQ:AKTX) and Arbutus Biopharma (NASDAQ:ABUS) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Moderna (NasdaqGS:MRNA) Sees 15% Jump Despite Recent Revenue Challenges - Yahoo Finance

Mar 09, 2025
pulisher
Mar 08, 2025

FY2025 Earnings Forecast for ABUS Issued By Chardan Capital - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Are Arbutus Biopharma Corp’shares a good deal? - US Post News

Mar 07, 2025
pulisher
Mar 07, 2025

Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction - Yahoo Finance

Mar 07, 2025
pulisher
Mar 04, 2025

Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360

Mar 04, 2025
pulisher
Mar 03, 2025

Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Genevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle Technology - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - StockTitan

Mar 03, 2025
pulisher
Feb 28, 2025

Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

StockNews.com Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Sell - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Brokers Issue Forecasts for ABUS FY2029 Earnings - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Brokers Set Expectations for ABUS FY2029 Earnings - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Arbutus Biopharma (NASDAQ:ABUS) Lowered to “Sell” Rating by StockNews.com - Defense World

Feb 26, 2025
pulisher
Feb 26, 2025

Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo

Feb 26, 2025
pulisher
Feb 25, 2025

Lindsay Androski named CEO of Arbutus - BioCentury

Feb 25, 2025
pulisher
Feb 25, 2025

Arbutus Biopharma appoints new CEO and reshapes board - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - The Manila Times

Feb 25, 2025

Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):